| Drug Name |
Telavancin |
| Drug ID |
BADD_D02143 |
| Description |
Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others. |
| Indications and Usage |
For the treatment of complicated skin and skin structure infections (cSSSI) caused by gram-positive bacteria like methicillin-susceptible or -resistant Staphylococcus aureus, vancomycin-susceptible Enterococcus faecalis, and Streptococcus pyogenes, Streptococcus agalactiae, or Streptococcus anginosus group. Also for the treatment of adult patients with hospital-acquired bacterial pneumonia (HAP) and ventilator-associated bacterial pneumonia (VAP), known or suspected to be caused by susceptible isolates of Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant S. aureus). |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
J01XA03 |
| DrugBank ID |
DB06402
|
| KEGG ID |
D06057
|
| MeSH ID |
C487637
|
| PubChem ID |
3081362
|
| TTD Drug ID |
D0B9JO
|
| NDC Product Code |
71124-0005 |
| Synonyms |
telavancin | TD 6424 | TD6424 | TD-6424 | Vibativ | telavancin hydrochloride |
